Clinical Analysis Of Oxcarbazepine In The Treatment Of 54 Patients With Epilepsy

Objective: To analysis the usage of Oxcarbazepine(OXC), which is the new kind of antiepileptic drugs (AEDs). Methods: Review 54 epileptic patients with OXC monotherapy or adjunctive therapy to other AEDs, among which we mainly evaluate the efficacy, efficient time, efficient dosage, tolerability and safety. Results: The total effective rates were 68.52%. It is 75.61% of monotherapy and 46.15% of patients adjunct to other AEDs, which have the difference (p=0.046) with Chi-square test. The effective rate of new onset epilepsy with OXC as first-line treatment is 88.89%, respectively, 65.22% of patients who switch from other AEDs for poor efficacy or adverse event, receiving OXC as a second-line therapy. They have no significantly difference (p=0.080) with Chi-square test. The effective dose of this two subgroup is 487.50±139.64mg/d compare to 660.00±202.84mg/d, which have significantly difference with student t test (p=0.010); 13 patients have adverse event, among which 3 patient stop OXC for rash. Conclusion: There are good effective rates in new onset epilepsy with monotherapy OXC, as well as good safety and tolerability profiles.